AZD-7325
- Generic Name
- AZD-7325
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19FN4O2
- CAS Number
- 942437-37-8
- Unique Ingredient Identifier
- KNM216XOUH
- Background
AZD7325 is a high affinity, selective modulator of the GABAA receptor system.
Avenue Therapeutics Anticipates AJ201 Data, Reports Q3 2024 Results
• Avenue Therapeutics expects topline data from its Phase 1b/2a trial of AJ201 for spinal and bulbar muscular atrophy around year-end 2024.
• The Phase 1b/2a trial enrolled 25 patients to evaluate the safety and tolerability of AJ201 at 600 mg/day versus placebo.
• Avenue Therapeutics' Q3 2024 R&D expenses increased to $2.3 million, while the company reported a net loss of $3.1 million.
• Pending additional financing, Avenue plans to initiate a Phase 2a trial for BAER-101 in epilepsy and a Phase 3 safety study for IV tramadol.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath